People: Regeneron Pharmaceuticals Inc (REGN.OQ)
REGN.OQ on NASDAQ Stock Exchange Global Select Market
271.42USD
12:55pm EDT
271.42USD
12:55pm EDT
Price Change (% chg)
$-6.87 (-2.47%)
$-6.87 (-2.47%)
Prev Close
$278.29
$278.29
Open
$277.64
$277.64
Day's High
$277.64
$277.64
Day's Low
$271.36
$271.36
Volume
68,696
68,696
Avg. Vol
220,530
220,530
52-wk High
$283.00
$283.00
52-wk Low
$131.50
$131.50
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
P. Roy Vagelos |
83 | 1995 | Chairman of the Board |
Leonard Schleifer |
60 | 1994 | President, Chief Executive Officer, Director |
Murray Goldberg |
68 | 2000 | Chief Financial Officer, Senior Vice President - Finance and Administration, Assistant Secretary |
Joseph LaRosa |
54 | 2011 | Senior Vice President, General Counsel, Secretary |
Daniel Van Plew |
40 | 2008 | Senior Vice President, General Manager - Industrial Operations and Product Supply |
Peter Powchik |
56 | 2006 | Senior Vice President - Clinical Development |
Neil Stahl |
56 | 2007 | Senior Vice President - Research and Development Sciences |
Robert Terifay |
53 | 2007 | Senior Vice President - Commercial |
George Yancopoulos |
53 | 2001 | Chief Scientific Officer and President - Regeneron Laboratories, Director |
Douglas McCorkle |
56 | 2007 | Vice President, Controller, Assistant Treasurer |
Michael Aberman |
42 | 2010 | Vice President - Strategy and Investor Relations |
William Roberts |
55 | 2007 | Vice President - Regulatory Development and Medical Safety |
Charles Baker |
80 | 1989 | Independent Director |
Michael Brown |
72 | 1991 | Independent Director |
Alfred Gilman |
71 | 1990 | Independent Director |
Joseph Goldstein |
72 | 1991 | Independent Director |
Christine Poon |
61 | 2010 | Independent Director |
Arthur Ryan |
70 | 2003 | Independent Director |
Eric Shooter |
88 | 1988 | Independent Director |
George Sing |
63 | 1988 | Independent Director |
Marc Tessier-Lavigne |
53 | 2011 | Independent Director |
Biographies
| Name | Description |
|---|---|
P. Roy Vagelos |
Dr. P. Roy Vagelos, M.D., is Chairman of the Board of Regeneron Pharmaceuticals, Inc., since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc., a global pharmaceutical company. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos served on the board of directors of Theravance, Inc. through April 2010. |
Leonard Schleifer |
Dr. Leonard S. Schleifer, M.D., Ph.D., is President, Chief Executive Officer and Director of Regeneron Pharmaceuticals, Inc. Dr. Schleifer founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. |
Murray Goldberg |
Mr. Murray A. Goldberg is Chief Financial Officer, Senior Vice President - Finance and Administration, Assistant Secretary of Regeneron Pharmaceuticals, Inc., since December 2000. Prior to that date, he was Vice President, Finance and Administration, Chief Financial Officer, and Treasurer, positions he held since March 1995, and Assistant Secretary, a position he held since January 2000. Prior to joining the Company, Mr. Goldberg was Vice President, Finance, Treasurer, and Chief Financial Officer of PharmaGenics, Inc., a biotechnology company, from February 1991 and a Director of that company from May 1991. From 1987 to 1990, Mr. Goldberg was Managing Director, Structured Finance Group at the Chase Manhattan Bank, N.A. and from 1973 to 1987 he served in various managerial positions in finance and corporate development at American Cyanamid Company, a diversified industrial company. Mr. Goldberg received his M.B.A. from the University of Chicago and a M.Sc. in Economics from the London School of Economics. |
Joseph LaRosa |
Mr. Joseph J. LaRosa is Senior Vice President, General Counsel, Secretary of Regeneron Pharmaceuticals, Inc., since September 06, 2011. From 1993 to 2009, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Most recently Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed US Inc. Mr. LaRosa received his J.D. from New York University School of Law. |
Daniel Van Plew |
Mr. Daniel P. Van Plew is Senior Vice President and General Manager - Industrial Operations and Product Supply of Regeneron Pharmaceuticals, Inc., since April 2008. Prior to that date, he served as Vice President and General Manager, Industrial Operations and Product Supply since joining the Company in July 2007. From 2006 until July 2007, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, part of Chiron Corporation, a biotechnology company, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, Mr. Van Plew held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his M.S. in Chemistry from The Pennsylvania State University and his M.B.A. from Michigan State University. |
Peter Powchik |
Dr. Peter Powchik, M.D., is Senior Vice President - Clinical Development of Regeneron Pharmaceuticals, Inc., since October 3, 2006. Prior to joining the Company, Dr. Powchik was employed at several pharmaceutical companies, serving as Senior Vice President and Chief Medical Officer of Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporation, most recently as Vice President, US Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his M.D. from New York University School of Medicine. |
Neil Stahl |
Dr. Neil Stahl, Ph.D., is Senior Vice President - Research and Development Sciences of Regeneron Pharmaceuticals, Inc., since January 2007. Prior to that date, he served as Senior Vice President, Preclinical Development and Biomolecular Sciences, a position he held since December 2000. Prior to that date, he was Vice President, Preclinical Development and Biomolecular Sciences, a position he held since January 2000. He joined the Company in 1991. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction. Dr. Stahl received his Ph.D. in Biochemistry from Brandeis University. |
Robert Terifay |
Mr. Robert J. Terifay is Senior Vice President - Commercial of Regeneron Pharmaceuticals, Inc., since February 2007. Prior to joining the Company, Mr. Terifay was employed at several biopharmaceutical companies. From January to October 2006, Mr. Terifay served as President and Chief Operating Officer of Arginox Pharmaceuticals. Prior to his employment at Arginox, Mr. Terifay was Senior Vice President, Business Operations at Synta Pharmaceuticals from March to December 2005. From February 2002 until March 2005, he held various senior commercial and marketing positions at Millennium Pharmaceuticals, Inc., most recently as Senior Vice President, Oncology Commercial. Mr. Terifay was Vice President Marketing at Cor Therapeutics, Inc. from 1996 until its acquisition by Millennium Pharmaceuticals, Inc. in February 2002. Mr. Terifay was Executive Vice President of Strategic Services at Saatchi & Saatchi, an advertising firm, from 1993 to 1996. From 1985 to 1993, he held various commercial and marketing positions at G.D. Searle & Company. Mr. Terifay received his Master of Management degree in Marketing and Health Service Management from the J.L. Kellogg Graduate School of Management, Northwestern University. |
George Yancopoulos |
Dr. George D. Yancopoulos, M.D., Ph.D., is Chief Scientific Officer and President - Regeneron Laboratories, Director of Regeneron Pharmaceuticals, Inc., since June 14, 2001. He joined the Company in 1989 as its Founding Scientist and is currently President, Regeneron Laboratories and Chief Scientific Officer. While holding leadership positions, Dr. Yancopoulos headed the Company’s laboratories and science organization since joining the Company and, in 1998, was named the Company’s first Chief Scientific Officer. Dr. Yancopoulos joined the board in 2001. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of the Companuy’s three FDA-approved drugs, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use, as well as of its foundation technologies, including the TRAP technology, VelociGene®, and VelocImmune®. |
Douglas McCorkle |
Mr. Douglas S. McCorkle is Vice President, Controller and Assistant Treasurer of Regeneron Pharmaceuticals, Inc., since 2007. Prior to that date, he served as Controller and Assistant Treasurer since 1998. Prior to joining the Company, Mr. McCorkle was Controller of Intergen Company, a manufacturer of biopharmaceutical products, a position he held since 1997. From 1990 to 1996, Mr. McCorkle was employed with Coopers & Lybrand L.L.P., where he specialized in biotechnology clients and served in various positions including Audit Manager from 1995 to 1996. Mr. McCorkle is a Certified Public Accountant in the State of New York. |
Michael Aberman |
Dr. Michael Aberman, M.D., is Vice President - Strategy and Investor Relations of Regeneron Pharmaceuticals, Inc., since March 23, 2010. Prior to joining the Company, he spent six years as a Wall Street analyst covering the biotechnology industry. From March 2006 until joining the Company, he was Director and Senior Biotechnology Analyst at Credit Suisse. Prior to that, from March 2004 until March 2006, he worked as a Biotechnology Analyst at Morgan Stanley, Inc. From February 2002 through March 2004, Dr. Aberman was Director of Business Development at Antigenics Inc., an oncology-focused biotechnology company. Dr. Aberman received his M.D. with honors from the University of Toronto and his M.B.A. from the Wharton School of the University of Pennsylvania. |
William Roberts |
Dr. William G. Roberts, M.D., is Vice President - Regulatory Development and Medical Safety of Regeneron Pharmaceuticals, Inc., since June 2007. Prior to that date, he served as Vice President, Regulatory Development, a position he held since May 1999. From 1993 until joining the Company, Dr. Roberts was employed by Merck & Co., Inc., a global pharmaceutical company, as an Associate Director, Gastroenterology Clinical Research and, subsequently, Director, Regulatory Affairs. He received his M.D. from the Columbia University College of Physicians & Surgeons. |
Charles Baker |
Mr. Charles A. Baker, J.D., is an Independent Director of Regeneron Pharmaceuticals, Inc., since February 1989. In September 2000, Mr. Baker retired as Chairman, President, and Chief Executive Officer of The Liposome Company, Inc., a biopharmaceutical company, a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various other pharmaceutical companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb Company) and President, Squibb International, and various senior executive positions at Abbott Laboratories and Pfizer Inc. Mr. Baker is a member of the board of directors of Progenics Pharmaceuticals, Inc., a biopharmaceutical company. |
Michael Brown |
Dr. Michael S. Brown, M.D., is an Independent Director of Regeneron Pharmaceuticals, Inc., since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine, and Foreign Member of the Royal Society (London). Dr. Brown retired as a member of the board of directors of Pfizer Inc. in 2012. |
Alfred Gilman |
Dr. Alfred G. Gilman, M.D., Ph.D., is an Independent Director of Regeneron Pharmaceuticals, Inc., since July 1990. Dr. Gilman is a Regental Professor Emeritus of Pharmacology at The University of Texas Southwestern Medical Center at Dallas. He was the chief scientific officer of the Cancer Prevention and Research Institute of Texas from 2009 to 2012. He previously served as executive vice president for academic affairs and provost of The University of Texas Southwestern Medical Center at Dallas, dean of The University of Texas Southwestern Medical School, and professor of pharmacology at The University of Texas Southwestern Medical Center. Dr. Gilman is a member of the National Academy of Sciences, and he received the Nobel Prize for Physiology or Medicine in 1994. He is one of the inaugural fellows of the American Association of Cancer Research. Dr. Gilman is a member of the Board of Directors of Eli Lilly & Company. |
Joseph Goldstein |
Dr. Joseph L.Goldstein, M.D., is an Independent Director of Regeneron Pharmaceuticals, Inc., since June 1991. Dr. Goldstein has been a Professor of Molecular Genetics and Internal Medicine and the Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences, the Institute of Medicine, and the Royal Society (London). He also serves on the Boards of Trustees of The Rockefeller University and the Howard Hughes Medical Institute. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985. |
Christine Poon |
Ms. Christine A. Poon is an Independent Director of Regeneron Pharmaceuticals, Inc., since November 12, 2010. Ms. Poon is Dean and holds the John W. Berry, Sr. Chair in Business at The Max M. Fisher College of Business at The Ohio State University, a position she has held since 2009. Prior to joining Fisher, Ms. Poon spent eight years at Johnson & Johnson, most recently as vice chairman and worldwide chairman of pharmaceuticals. At Johnson & Johnson, she served on the company’s board of directors and executive committee and was responsible for managing the pharmaceutical businesses of the company. Prior to joining Johnson & Johnson, Ms. Poon spent 15 years at Bristol-Myers Squibb Company, a pharmaceutical company, where she held senior leadership positions including president of international medicines and president of medical devices. Ms. Poon serves on the board of directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. |
Arthur Ryan |
Mr. Arthur F. Ryan is an Independent Director of Regeneron Pharmaceuticals, Inc., since January 17, 2003. In 2008, Mr. Ryan retired as the Chairman of the Board of Prudential Financial, Inc. He served as Chief Executive Officer of Prudential until December 2007. Prior to joining Prudential in December 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan managed Chase’s worldwide retail bank between 1984 and 1990. Mr. Ryan is a non-executive director of the Royal Bank of Scotland Group plc. |
Eric Shooter |
Dr. Eric M. Shooter, Ph.D., is an Independent Director of Regeneron Pharmaceuticals, Inc., since 1998. Dr. Shooter has been a Professor at Stanford University School of Medicine since 1968 and is now a Professor Emeritus. He was the founding Chairman of the Department of Neurobiology at Stanford University School of Medicine in 1975 and served as its Chairman until 1987. Dr. Shooter is a Fellow of the Royal Society of London and a member of the National Academy of Sciences. |
George Sing |
Mr. George L. Sing is an Independent Director of Regeneron Pharmaceuticals, Inc., since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Since January 2004, Mr. Sing has served as Chief Executive Officer of Stemnion, Inc., a bio-medical company in the regenerative medicine field. |
Marc Tessier-Lavigne |
Dr. Marc Tessier-Lavigne, Ph.D., is Independent Director of Regeneron Pharmaceuticals, Inc., since November 21, 2011. Dr. Tessier-Lavigne has been the President of The Rockefeller University since March 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne is a member of the National Academy of Sciences, the Institute of Medicine, and a fellow of the Royal Societies of the United Kingdom and Canada. Dr. Tessier-Lavigne is a member of the Board of Directors of Pfizer Inc. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
P. Roy Vagelos |
-- |
Leonard Schleifer |
30,047,100 |
Murray Goldberg |
9,623,070 |
Joseph LaRosa |
-- |
Daniel Van Plew |
2,188,990 |
Peter Powchik |
-- |
Neil Stahl |
11,995,200 |
Robert Terifay |
7,478,310 |
George Yancopoulos |
81,551,400 |
Douglas McCorkle |
-- |
Michael Aberman |
-- |
William Roberts |
-- |
Charles Baker |
-- |
Michael Brown |
-- |
Alfred Gilman |
-- |
Joseph Goldstein |
-- |
Christine Poon |
-- |
Arthur Ryan |
-- |
Eric Shooter |
-- |
George Sing |
-- |
Marc Tessier-Lavigne |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
P. Roy Vagelos |
0 | 0 |
Leonard Schleifer |
2,401,491 | 55,714,160 |
Murray Goldberg |
617,848 | 19,829,724 |
Joseph LaRosa |
0 | 0 |
Daniel Van Plew |
25,000 | 277,500 |
Peter Powchik |
0 | 0 |
Neil Stahl |
905,012 | 39,832,170 |
Robert Terifay |
119,955 | 12,801,500 |
George Yancopoulos |
2,148,211 | 31,385,960 |
Douglas McCorkle |
0 | 0 |
Michael Aberman |
0 | 0 |
William Roberts |
0 | 0 |
Charles Baker |
0 | 0 |
Michael Brown |
0 | 0 |
Alfred Gilman |
0 | 0 |
Joseph Goldstein |
0 | 0 |
Christine Poon |
0 | 0 |
Arthur Ryan |
0 | 0 |
Eric Shooter |
0 | 0 |
George Sing |
0 | 0 |
Marc Tessier-Lavigne |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
ABERMAN MICHAEL S |
3,900 | $24.00 |
BAKER CHARLES A |
200 | $255.16 |
BAKER CHARLES A |
300 | $257.99 |
BAKER CHARLES A |
15,000 | $15.80 |
BAKER CHARLES A |
4,748 | $252.32 |
BAKER CHARLES A |
756 | $254.10 |
BAKER CHARLES A |
4,150 | $250.06 |
BAKER CHARLES A |
908 | $253.50 |
BAKER CHARLES A |
3,938 | $251.67 |
RYAN ARTHUR F |
500 | $249.45 |
RYAN ARTHUR F |
2,000 | $249.58 |
GOLDSTEIN JOSEPH L |
4,000 | $252.20 |
RYAN ARTHUR F |
3,000 | $0.00 |
GOLDBERG MURRAY A |
1,910 | $262.14 |
GOLDBERG MURRAY A |
3,071 | $20.32 |
GOLDBERG MURRAY A |
3,516 | $257.59 |
GOLDBERG MURRAY A |
8,989 | $258.54 |
GOLDBERG MURRAY A |
9,561 | $256.61 |
GOLDBERG MURRAY A |
8,774 | $261.36 |
GOLDBERG MURRAY A |
2,200 | $263.89 |
GOLDBERG MURRAY A |
952 | $16.80 |
GOLDBERG MURRAY A |
4,061 | $0.00 |
GOLDBERG MURRAY A |
3,000 | $264.61 |
GOLDBERG MURRAY A |
18,542 | $260.57 |
GOLDBERG MURRAY A |
1,777 | $255.52 |

